GlaxoSmithKline plc (GSK) – Cabenuva ,the world’s first and only HIV treatment

The company is reshaping the landscape of HIV treatment with the launch of Cabenuva , the world’s first and only treatment. It also achieved important regulatory milestones with the approvals of Rukobia and
dostarlimab .

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage 

No of Pages : 35